[1] Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med, 2015; 5, a021535. doi:  10.1101/cshperspect.a021535
[2] Thomas HE, Mercer CA, Carnevalli LS, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med, 2012; 4, 139ra84.
[3] Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer, 2018; 4, 418−28. doi:  10.1016/j.trecan.2018.04.001
[4] Luo YJ, Yao YX, Wu P, et al. The potential role of N7-methylguanosine (m7G) in cancer. J Hematol Oncol, 2022; 15, 63. doi:  10.1186/s13045-022-01285-5
[5] Gao ZJ, Xu JY, Zhang ZP, et al. A comprehensive analysis of METTL1 to immunity and stemness in Pan-Cancer. Front Immunol, 2022; 13, 795240. doi:  10.3389/fimmu.2022.795240
[6] Ma JY, Han H, Huang Y, et al. METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression. Mol Ther, 2021; 29, 3422−35. doi:  10.1016/j.ymthe.2021.08.005
[7] Chen Z, Zhang Z, Ding W, et al. Expression and potential biomarkers of regulators for M7G RNA modification in gliomas. Front Neurol, 2022; 13, 886246. doi:  10.3389/fneur.2022.886246
[8] Schabath MB, Welsh EA, Fulp WJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene, 2016; 35, 3209−16. doi:  10.1038/onc.2015.375
[9] St Paul M, Ohashi PS. The Roles of CD8 T Cell Subsets in Antitumor Immunity. Trends Cell Biol, 2020; 30, 695-704. doi:  10.1016/j.tcb.2020.06.003IF:4.996Q2B3
[10] Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol, 2020; 72, 320−41. doi:  10.1016/j.jhep.2019.10.021